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Background: This study measured longitudinal changes in dry eye disease (DED) symptoms 
and signs following lifitegrast therapy and assessed their relationship to tear osmolarity to test 
the hypothesis that a decline in tear osmolarity is a reliable leading indicator of subsequent 
improvement in DED symptoms and signs after initiating lifitegrast treatment.
Methods: This phase IV, prospective, single-arm, open-label, 12-week study enrolled subjects 
aged $18 years with eye dryness score $40 (0–100 VAS) and tear osmolarity $308 mOsm/L. 
Subjects were prescribed lifitegrast ophthalmic solution 5%, twice daily in each eye. DED 
symptoms were assessed via VAS at baseline and 2, 6, and 12 weeks. Signs included tear 
osmolarity, meibomian gland dysfunction, tear breakup time, and fluorescein corneal staining. 
In post-hoc analysis, subjects with $5 mOsm/L decrease in osmolarity over 12 weeks were 
Responders.
Results: Of 26 subjects in the intent-to-treat population, 23 were female; mean age 
was 67.4 years. Baseline mean±SD eye dryness was 68.7±16.5 and tear osmolarity was 
317.8±8.5 mOsm/L. All seven symptoms (dryness, burning, foreign body sensation, pain, 
photophobia, itching, blurred vision) declined significantly (P,0.01) from baseline to 6 and 
12 weeks. Signs did not change significantly. For 13 Responders, tear osmolarity decreased 
from baseline to 12 weeks (319.2±8.5 to 300.6±12.3 mOsm/L, P,0.001) and corneal staining 
trended toward improvement (1.1±0.9 to 0.6±0.7, P=0.136). Among Nonresponders, osmolarity 
increased from 316.4+8.7 to 329.6+13.9 (P,0.01) and corneal staining showed no change 
(1.3±0.8 to 1.0±0.7 at 12 weeks, P=0.293).
Conclusions: Lifitegrast reduced DED symptoms among subjects with moderate-to-severe 
disease (severity defined by VAS for eye dryness). Potential reasons that may underlie the 
dichotomous effect of drug treatment on tear osmolarity are discussed.
Keywords: dry eye, ocular drug therapy, tear deficiency, lifitegrast
Introduction
Dry eye disease (DED) is a multifactorial disorder characterized by symptoms of 
discomfort and visual disturbance.1 In the Tear Film and Ocular Surface Society 
International Dry Eye Workshop II, the revised definition of DED recognizes the 
etiological roles of loss of tear film homeostasis, elevated tear osmolarity, and ocular 
surface inflammation and damage.1 Based on available evidence, it has been sug-
gested that rapid breakup of the unstable tear film after blinking leads to drying of the 
ocular surface and hyperosmolarity of the tear film. These local changes can in turn 
elicit inflammation and cell death, and they may be accompanied by neurosensory 
abnormalities.2
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Tear film hyperosmolarity has been well established as a 
key feature in the diagnosis of DED that is quantitatively asso-
ciated with disease severity.3 Normal tear osmolarity is tightly 
regulated and maintained between 280 and 300 mOsm/L.4 
Tear osmolarity .308 mOsm/L, or a difference between eyes 
of .8 mOsm/L, is a widely accepted cut-off for diagnosis of 
DED, and osmolarity of $316 mOsm/L likely indicates 
moderate-to-severe DED.5
Hyperosmolarity is a central pathophysiological mecha-
nism for all forms of DED.6 It has also been shown to produce 
apoptosis of ocular surface cells along with inflammation via 
the mitogen-activated protein kinase pathways.7 Hyperosmolar 
stress induces production of proinflammatory cytokines8 
such as IL-1β, tumor necrosis factor-α, the chemokine 
IL-8, matrix metalloproteinase-9 (MMP-9),9,10 and human 
leukocyte antigen–antigen D related.11 Hyperosmolarity 
and inflammation create a vicious cycle, leading to loss of 
homeostatic mechanisms, tear film instability, and neuro-
sensory abnormalities.2
In an analysis of commonly used objective clinical tests 
for DED, tear osmolarity was the most stable measure and 
also the most sensitive to changes in tear physiology.3 In a 
3-month observational case series study of 10 patients with 
severe DED, tear osmolarity declined significantly from 
a mean of 341 mOsm/L to 307 mOsm/L after treatment 
with cyclosporine A, whereas other signs did not exhibit 
a statistically significant treatment response.3 Similarly, 
1 month following cataract surgery in 30 subjects (60 eyes) 
randomized between topical cyclosporine A 0.05% emul-
sion and 0.5% carboxymethylcellulose drops, a statisti-
cally significant reduction in mean tear osmolarity was 
demonstrated favoring the cyclosporine A group over the 
carboxymethylcellulose cohort, along with similar statisti-
cally significant improvement in ocular surface staining, tear 
breakup time (TBUT), and Schirmer’s I testing.12 In another 
study of 105 patients with DED, tear osmolarity declined 
from a mean of 326 mOsm/L at baseline to 307 mOsm/L at 
12 weeks after treatment with omega-3 nutritional supple-
ments, a reduction that was statistically greater than with 
placebo.13 Similar reduction in tear osmolarity, averaging 
18.6 and 19.8 mOsm/L, respectively, was reported following 
a 3-month daily dose of krill oil and fish oil supplements, 
with olive oil supplementation, serving as the placebo 
control, showing no significant reduction (average change 
1.5 mOsm/L).14 In these and other studies, analysis based 
on the eye with the worse/more severe measurement at each 
time-point provided a more sensitive test and also a more 
stringent requirement for assessment of response.3,13–19 Tear 
osmolarity emerged in these and other studies13–19 as a precise 
objective measure to quantitatively track the effects of diverse 
DED therapies. A decline in tear osmolarity after initiating 
treatment emerged as a leading indicator of subsequent 
improvement in other signs and symptoms.
Lifitegrast ophthalmic solution 5% was recently approved 
in the USA for treatment of signs and symptoms of DED.20 
Lifitegrast is an antagonist of lymphocyte function-associated 
antigen-1, which binds with its cognate ligand, intercellular 
adhesion molecule-1, to evoke an immune response that 
causes ocular surface inflammation.21,22 Findings from in vitro 
studies demonstrate that lifitegrast inhibits the recruitment of 
previously activated T cells, the activation of newly recruited 
T cells, and the release of pro-inflammatory cytokines, effects 
that may interrupt the cycle of inflammation in DED.21,23,24
Approval of lifitegrast was based on a phase II trial25 and 
three phase III trials (OPUS-1,26 OPUS-2,27 and OPUS-328), 
each conducted in adults with DED. In the phase II trial, 
lifitegrast 5.0% did not meet the primary endpoint of corneal 
staining, a sign of DED, at day 84, but did meet prespeci-
fied secondary endpoints of change from baseline in corneal 
staining and in a visual-related function subscale of a symp-
tom scale.25 In OPUS-1, lifitegrast achieved the co-primary 
endpoint for reduction of corneal staining but did not meet the 
co-primary endpoint for reduction of subjective symptoms.26 
In OPUS-2, the opposite pattern emerged, as lifitegrast met 
the co-primary endpoint of reduction in eye dryness, a key 
symptom, but did not reduce corneal staining, the other 
co-primary endpoint.27
Holland et al observed that the phase II study and OPUS-1 
were conducted in patients with mild-to-moderate DED, 
whereas OPUS-2 was conducted in patients with moderate-
to-severe disease (baseline eye dryness score $40 out of 100 
on a VAS).29 Based in part on results of post-hoc analyses, 
Holland et al suggested that the differing patterns of find-
ings between the phase II, OPUS-1, and OPUS-2 trials may 
have resulted from differences in baseline disease severity 
in the study populations; specifically, lifitegrast improved 
signs in patients with mild-to-moderate disease (phase II and 
OPUS-1 studies) and improved symptoms in patients with 
moderate-to-severe disease (OPUS-2).29 The final phase III 
lifitegrast study, OPUS-3, was conducted in patients with 
moderate-to-severe DED (baseline eye dryness score $40) 
and met the primary endpoint of reduction in eye dryness,28 
confirming the finding for symptoms in OPUS-2. Lifitegrast 
has also been shown to be comfortable on administration30 
and safe and well tolerated over 1 year of use.31
Given the established utility of tear osmolarity to track 
effects of DED therapies,3,12–19 it would be of interest to 
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lifitegrast therapy and assess the relationship of tear osmolar-
ity to overall changes in symptoms and signs of DED. The 
purpose of this study was to test the hypothesis that a fall in 
tear osmolarity would be a leading indicator of a subsequent 
decrease in symptoms in patients with DED treated with 
topical lifitegrast therapy and followed for 12 weeks.
Materials and methods
This was a phase IV, prospective, single-arm, open-label, 
12-week, longitudinal study (ClinicalTrials.gov identifier: 
NCT03451396) conducted between December 12, 2016 and 
March 15, 2018. The study was conducted at two sites in 
the USA under the approval of the Sterling Investigational 
Review Board (Atlanta, GA, USA). The study adhered to 
the principles of the Declaration of Helsinki.
subjects
Up to 30 subjects were intended to be recruited, in two 
groups of 15 subjects each. All subjects were $18 years of 
age and had been diagnosed with DED with VAS score for 
eye dryness $40 (0–100 scale). In Group 1, subjects had 
tear osmolarity $308 and ,320 mOsm/L in at least one 
eye. In Group 2, subjects had tear osmolarity $320 mOsm/L 
in at least one eye. Subjects had to be willing to adhere to 
twice-daily (b.i.d.) dosing and the follow-up visit schedule, 
and agree not to otherwise change their medication regimen.
Exclusion criteria included a history of ocular pathol-
ogy, degeneration, or allergy; receipt of any T-cell modula-
tory therapy; instillation of artificial tears within 2 hours of 
study visit; contact lens use; eye or eyelid surgery in the past 
6 months; change in dry eye therapy in the past 2 months; 
and participation in any concurrent clinical trial. All subjects 
completed an informed consent form indicating their volun-
tary participation in the study.
study design and treatment
At Visit 1, eligible subjects were prescribed lifitegrast oph-
thalmic solution 5% (Xiidra®; Shire, a Takeda company, 
Lexington, MA, USA), one drop b.i.d. in each eye. Investi-
gational product compliance along with any possible adverse 
events was reviewed with the subject at each visit. Treatment 
was maintained for the duration of the 12-week study period. 
Subjects were instructed not to change their habitual use of 
medications, artificial tears, or supplements when starting 
the study drug.
Xiidra (lifitegrast ophthalmic solution) 5% is a lym-
phocyte function-associated antigen-1 (LFA-1) antagonist 
supplied as a sterile, preservative-free, clear, colorless 
to slightly brownish-yellow colored, isotonic solution of 
lifitegrast with a pH of 7.0–8.0 and an osmolality range of 
200–330 mOsmos/kg in single-unit-dose ampules. The active 
ingredient in Xiidra is lifitegrast 50 mg/mL; the inactive 
ingredients are buffered saline comprised of sodium chloride, 
sodium phosphate dibasic anhydrous, sodium thiosulfate 
pentahydrate, sodium hydroxide and/or hydrochloric acid 
(to adjust pH), and water for injection.
Outcome measures
Symptoms of DED were measured by the VAS, a subject-
reported index in which each item is reported on a 0–100 
scale (0 = none; 100 = severe). Items included eye dryness, 
burning/stinging, foreign body sensation, pain, photophobia, 
itching, and blurred vision.
Signs of DED were measured by tear osmolarity (mea-
sured as mOsm/L using the TearLab™ Osmolarity System), 
meibomian gland dysfunction (MGD) grading (0–5 scale; 
visual grading of meibomian gland clogging on examination 
and expression), TBUT (the timing of the breakup of the 
precorneal tear film [in seconds] following a blink), and fluo-
rescein corneal and conjunctival staining score (0–5 scale; 
area and density of cornea and conjunctival staining with 
fluorescein dye uptake accessed via slit-lamp examina-
tion using a cobalt blue filter, using the Oxford scheme as 
described by Bron et al32).
Meibomian gland function was graded as follows. Grade 0 
indicated normal-appearing, functioning meibomian glands 
with clear oil discharge and no dropout or plugging. Grade 1 
demonstrated only subclinical changes with altered meibum 
quality on expression and no gland dropout. Grade 2 showed 
minimally altered quality of expressed meibum from scat-
tered glands with minor gland loss. Grade 3 demonstrated 
mildly altered meibum quality, occasional lid margin signs, 
and mild gland loss. Grade 4 showed moderately increased 
opacity and viscosity of meibum, plugging, increased mar-
ginal vascularity, loss of orifice definition, and moderate 
gland loss. Grade 5 indicated moderately increased opacity 
and viscosity of meibum, plugging, increased marginal vas-
cularity, loss of orifice definition, and moderate gland loss.
Osmolarity tear testing preceded all other diagnostic 
examinations, testing, staining, and instillation of study eye 
drops. Procedures followed the TearLab instruction guide, 
using a lab-on-a-chip system to simultaneously collect and 
analyze the electrical impedance of a 50 nL tear sample from 
the inferior lateral tear meniscus. Osmolarity was measured 
in both eyes, and data analysis is based on the eye with the 
higher reading at each time-point. For quality control, each 
Tear Lab pen was tested and recorded each day using the 
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on the high-osmolarity control solution, as per the TearLab 
instruction guide.
Study measurements were made at baseline (first clinic 
visit; Visit 1) and 2 weeks (Visit 2), 6 weeks (Visit 3), and 
12 weeks (Visit 4) following initiation of lifitegrast therapy. 
Compliance to study medication was confirmed at each visit, 
along with documentation of any adverse events.
statistical methods
The intent-to-treat (ITT) population included all subjects 
who received at least one dose of investigational product. 
All efficacy analyses were performed on the ITT population.
In the ITT population, descriptive statistics (mean and 
SD) were calculated for each visit. Signs and symptoms at 
each visit were compared with baseline (Visit 1) and previ-
ous visits using a two-tailed Student’s t-test. Signs were 
compared using the more severe eye at each visit to improve 
sensitivity, given the small sample size. The planned enroll-
ment of 30 subjects included a 20% attrition to achieve .80% 
power based on an alpha error of 0.05, a mean reduction in 
tear osmolarity of 10 mOsm/L, and SD of 8 mOsm/L.
For the responder analysis, which was conducted post 
hoc, subjects were classified according to improvement 
in tear osmolarity. Those who experienced a $5 mOsm/L 
decrease in tear osmolarity from baseline to 12 weeks 
were classified as Responders, and those who experi-
enced ,5 mOsm/L reduction or increase in osmolarity from 
baseline were Nonresponders. Descriptive statistics and 
visit-to-visit comparisons as described in the ITT analysis 
were repeated within these two groups. Baseline differences 
in signs and symptoms were compared between the groups 
to identify a physiological basis for Responder status.
Results
subject disposition and characteristics
In total, 30 subjects were enrolled, 15 in each group. Four 
subjects withdrew consent before the end of the study. 
In Group 1, one subject did not feel that their condition 
improved and discontinued study medication. In Group 2, 
three subjects withdrew owing to adverse reactions (burning, 
burning and blurred vision, and marginal ulcer). Overall, 
26 subjects completed the study and were included in efficacy 
analyses (ITT population).
Of the 26 subjects in the ITT population, 23 were female, 
and mean±SD age was 67.4±9.6 years. Of all subjects, 24 
were white/Caucasian, one was black, and one was Hispanic. 
All subjects had been on a steady, ongoing regimen without 
changes for a minimum of 3 months prior to study enrollment.
At baseline (Visit 1), mean±SD symptom scores were 
dryness, 68.7±16.5; burning, 50.0±24.4; foreign body sensa-
tion, 47.7±32.1; pain, 33.3±34.7; photophobia, 51.9±34.7; 
itching, 49.2±31.0; and blurred vision, 54.0±30.4, each out 
of 100. Mean±SD baseline levels for signs (more severe 
eye) were tear osmolarity, 317.8±8.5 mOsm/L; MGD grade, 
2.5±1.1 out of 5; TBUT, 4.9±2.3 seconds; and corneal stain-
ing score, 1.2±0.8 out of 5.
Outcomes: symptoms
Statistically significant (P,0.01) reductions from baseline 
(Visit 1) in VAS scores were observed for all seven symp-
toms at 6 weeks (Visit 3) and 12 weeks (Visit 4) (Figure 1). 
At 2 weeks (Visit 2), dryness, burning, foreign body sensa-
tion, pain, and itching scores were significantly lower than 
at baseline (P,0.05). Similar findings were observed when 
the two groups were stratified according to osmolarity 
($308 mOsm/L and $320 mOsm/L).
Outcomes: signs
Measures for signs did not differ significantly from baseline 
at any time-point (Figure 2). There was a downward trend 
for tear osmolarity at 2 weeks (P=0.080 vs baseline), but 
this trend was not sustained over 12 weeks. There was a 
downward trend for corneal staining (P=0.070 at 12 weeks 
vs baseline). No statistically significant differences were 
noted when stratifying the groups according to osmolarity.
responder analysis
Of the 26 subjects, 13 met the Responder criterion and 
13 were Nonresponders. For Responders, mean±SD tear 
Figure 1 Dry eye symptoms over time, expressed as Vas score (iTT population, 
n=26).
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osmolarity decreased significantly from 319.2±8.5 mOsm/L 
at baseline to 300.6±12.3 mOsm/L at 12 weeks (P,0.001 
vs baseline) (Figure 3). For Nonresponders, mean±SD tear 
osmolarity increased from 316.4±8.7 mOsm/L at baseline to 
329.6±13.9 mOsm/L at 12 weeks (P,0.01).
For Responders, mean±SD corneal staining score trended 
toward improvement from 1.1±0.9 at baseline to 0.6±0.7 at 
12 weeks (P=0.136 vs baseline) (Figure 4). Nonresponders 
experienced a smaller numeric reduction in mean±SD cor-
neal staining score, from 1.3±0.8 at baseline to 1.0±0.7 at 
12 weeks (P=0.293).
Responders also showed a trend toward higher pho-
tophobia scores at baseline (mean VAS score 61.9) than 
Nonresponders (mean 41.9; P=0.145).
Table 1 lists the distribution of pertinent medications, 
supplements, and artificial tear use in the Responder and 
Nonresponder cohorts. Two subjects in the Nonresponder 
group had plugs placed in both lower lid puncta more than 
1 year prior to study enrollment.
Discussion
In this 12-week study, a statistically significant reduction 
from baseline in symptoms measured by VAS was uniformly 
observed in the ITT population across seven symptoms 
at 6 and 12 weeks after initiation of lifitegrast therapy 
(Figure 1). This statistical difference emerged at 2 weeks after 
baseline for five of the symptoms: dryness, burning/sting-
ing, foreign body sensation, pain, and itching. The marked 
reduction in symptoms persisted for the full 12 weeks of the 
study, making it unlikely that this was a transient placebo 
effect. In contrast to the findings for symptoms, there was 
Figure 2 Dry eye signs over time, expressed as proportion of baseline score 
(iTT population, more severe eye, n=26).
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Figure 3 Tear osmolarity over time for subjects who showed strongly decreased 
osmolarity at the end of the study (responders, n=13) and subjects who showed 
little change or increased osmolarity (nonresponders, n=13).







Figure 4 Corneal fluorescein staining grade over time for subjects who showed 
strongly decreased osmolarity at the end of the study (responders, n=13) and 
subjects who showed little change or increased osmolarity (nonresponders, n=13).






Table 1 Subjects’ use of medications, artificial tears, and 
supplements
Pertinent medication 







Artificial tears 4 (30.7) 5 (38.4)
Omega-3/fish oil 5 (38.4) 0 (0)
Punctal plugs 0 (0) 2 (15.4)
antidepressant (atypical) 0 (0) 5 (38.4)
antidepressant (ssri) 4 (30.7) 5 (38.4)
antidepressant (tricyclic) 1 (7.7) 0 (0)
antihistamine 2 (15.4) 3 (23.1)
antipsychotic 1 (7.7) 0 (0)
Beta blocker 1 (7.7) 2 (15.4)
Conjugated estrogen 1 (7.7) 0 (0)
Diuretic 3 (23.1) 1 (7.7)
Muscle relaxant 1 (7.7) 1 (7.7)
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no significant improvement in any sign over the course of 
the study (Figure 2).
In analyzing the ITT group as a whole, the results failed 
to support the hypothesis that tear osmolarity was a reliable 
leading indicator for a subsequent fall in symptoms or signs 
in patients with DED given a 12-week course of topical 
lifitegrast. In a post-hoc analysis, the subset of subjects who 
responded to lifitegrast therapy with improvement in tear 
osmolarity also showed a trend toward reduction in cor-
neal staining, whereas both Responder and Nonresponder 
groups showed a statistically significant reduction in seven 
symptoms over the 12-week study. It is possible that these 
divergent results could indicate that a longer treatment dura-
tion might be required in the Nonresponder group to show a 
statistically significant reduction in corneal staining or tear 
osmolarity, or that other inflammatory signs may be better 
aligned with the core mechanism of lifitegrast.
While in vitro studies indicate that lifitegrast inhibits 
the activation and recruitment of T cells and the release of 
pro-inflammatory cytokines,21,23,24 the exact mechanism of 
action of lifitegrast in DED remains unknown. In an attempt 
to explain both the high efficacy of lifitegrast in quickly and 
uniformly reducing DED symptoms in subjects of this study 
and the paradoxical dichotomous effect on tear osmolarity, 
we propose the following testable hypothesis. Perhaps lifite-
grast could be more uniformly directly or indirectly affecting 
corneal neurosensory function in patients with moderate-
to-severe dry eye symptoms in addition to competitively 
blocking the LFA-1/ICAM-1 synapse. Notwithstanding this 
proposed neurosensory effect, Responder and Nonresponder 
groups could differ in levels or markers of inflammation 
and apoptosis, and thereby respond differently to this drug 
in terms of tear osmolarity and possibly corneal staining. 
An intriguing observation, in line with the hypothesis that 
lifitegrast could in some way affect corneal neurosensory 
function, is that Responders also had higher photophobia 
scores at presentation. Whereas photophobia is a symptom 
commonly associated with dry eye, it has been suggested that 
dry eye patients with photophobia may have a more severe 
form of dry eye than their counterparts without photophobia, 
and they may also be more likely to have a component of 
neuropathic pain.33 This finding and its association with the 
Responder group deserve additional future study.
The overall strong effect of lifitegrast for symptoms of 
DED in this study, alongside the lack of effect for signs, is 
not surprising given the pattern of results in earlier lifitegrast 
clinical trials. As in the OPUS-2 trial,27 this study enrolled 
subjects with moderate-to-severe DED (baseline eye dryness 
score $40) and found a significant effect for symptoms but 
no effect for signs. As Holland et al argued, 12 weeks may 
be too short a time period to overcome underlying condi-
tions and demonstrate objective improvement in the eye 
surface.28 It is also possible that subjects who experienced a 
relief of symptoms may have discontinued artificial tears or 
omega-3 supplements, counteracting any effect of lifitegrast 
on signs. That explanation seems less likely in our study, 
as we recorded both prescription and over-the-counter sys-
temic medications, drops, and supplements at every visit, 
and emphasized the importance of not changing the dosing; 
however, other ophthalmology drug studies have documented 
poor compliance with drug instructions even when patients 
report otherwise.34 An effect for signs may also be difficult 
to demonstrate in a study with a small number of subjects. 
Indeed, there was a trend toward improvement in corneal 
staining (P=0.070 at 12 weeks vs baseline), but the effect 
failed to reach significance. It is well recognized that objec-
tive signs and subjective symptoms of DED are not well 
correlated,35 so it is not surprising to demonstrate an effect for 
symptoms that are not accompanied by improvement in signs.
Examination of findings for Responders (subjects who 
experienced a strong improvement in tear osmolarity) may 
shed further light on the pattern of response to lifitegrast in 
this study, which was the purpose of performing this post-hoc 
analysis. Among Responders, mean corneal staining scores 
were stable until after Visit 2, after which staining scores 
reduced markedly between 2 and 6 weeks, for an overall 
numeric reduction of ~0.5 grades by 12 weeks (Figure 4). 
The improvement in the Nonresponder group, on average, 
was less than half a grade of staining, which we consider 
clinically indistinguishable from the original grade. Given the 
small sample size, these data must be interpreted accordingly.
The wide divergence in response for tear osmolarity 
between the Responder and Nonresponder groups (Figure 3) 
also reinforces the possibility that patients presenting with 
DED signs and symptoms may have differing underlying 
pathologies and disease etiologies.1 However, patients with 
predominantly aqueous or evaporative DED and combined 
mechanism DED may be mixed together in typical dry eye 
ITT groups. To further highlight the potential effects of such 
heterogeneity, Aragona et al found different expressions of 
MMP-9 and transglutaminase 2 and a differential response 
to steroid treatment among dry eye patients with Sjögren 
syndrome compared to those with MGD,36 and Perumal 
et al demonstrated differential expression of proteins in the 
tears of patients with aqueous-deficient versus evaporative 
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a subtype of DED patients that could be characterized to 
identify patients who are most likely to benefit from lifite-
grast therapy – perhaps those with particular inflammatory 
profiles. Future randomized, controlled studies using tear 
osmolarity and quantitative MMP-9 metrics in addition to 
other tear biomarkers may reveal additional information 
about the response to lifitegrast therapy in patients with dif-
ferent forms of DED.
We also noted that five of 13 patients in the Responder 
group, but no Nonresponders, had been taking oral omega-3/
fish oil supplementation, and studies have shown that initiat-
ing such supplementation may lead to a statistically significant 
fall in tear osmolarity as early as 4–6 weeks.13,14 In contrast 
to these studies, where oral omega-3/fish oil supplements 
had been newly initiated, leading to a relatively rapid fall in 
osmolarity, in our study these patients had been chronically 
on this supplement regimen for a minimum of 3 years and 
the difference in osmolarity between the two groups was not 
noted until week 12, at which point the Responder group 
was within the range of normal tear osmolarity. Given the 
chronic use of the same dosage of fish oil in this subset of the 
Responder group and the comparatively delayed time-course 
of the fall in tear osmolarity, it seems therefore unlikely that 
fish oil use represents a pertinent confounding variable that 
could explain the difference between Responders and Non-
responders. Also, there was minimal change in the grading 
of MGD in Responder and Nonresponder groups during the 
course of the study.
Limitations of this study include the small sample size and 
lack of a control group. Whereas a placebo effect is a possible 
explanation for response to therapy in the absence of a control 
group, generally placebo effects are of short duration. Sub-
jects in this study noted persistent improvement in symptoms 
over the 12-week study period, in confirmation of the OPUS 
trial results.8–24 Indeed, the entry criteria of this study closely 
paralleled OPUS-2 and the results regarding VAS for dry eye 
virtually mirrored the OPUS-2 results.27 The mean VAS for 
ocular dryness in this study was 68.7 and in OPUS-2 it was 
69.45. At 2, 6, and 12 weeks, in both studies, the dryness VAS 
dropped by 20, 30, and 35 points. In contrast, in the OPUS-2 
study, in the control group, treated with just the vehicle, the 
VAS for ocular dryness dropped by 13, 18, and 23 points at the 
same time-points, thereby creating a historical control group 
for the DED symptom VAS for the present study.
In conclusion, the findings of this study add to the body 
of literature demonstrating the efficacy of lifitegrast for treat-
ment of DED symptoms.24–28 Future research incorporating 
objective quantified measurement of inflammatory markers 
in the tear film may identify patients who will benefit most 
from lifitegrast therapy in reducing symptoms and/or signs, 
as well as the appropriate biomarkers to optimally monitor 
the results of therapy.
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